The Latest in DLBCL

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL

December 10, 2020

CAR T for all R/R DLBCL patients: The jury is still out

October 28, 2020

Seven things to know about new lymphoma drug tafasitamab

October 9, 2020

Survey quantifies COVID-19’s impact on oncology

September 20, 2020

FDA approves new drug for diffuse large B-cell lymphoma

August 4, 2020

HSCT or systemic treatment should be offered to HIV+ patients with lymphoma

July 16, 2020

FDA approves selinexor for relapsed/refractory DLBCL

June 23, 2020

Adding avadomide shows promise for newly diagnosed DLBCL

June 5, 2020

Race and location appear to play a role in the incidence of CLL and DLBCL

May 20, 2020

DLBCL patients at academic centers had significantly better survival

May 11, 2020

Safer CAR uses modified NK cells for advanced CLL, NHL

February 19, 2020

DLBCL tops cases of HBV-associated NHL in Europe

February 10, 2020

DLBCL

REGN1979 shows good activity in pretreated aggressive B-NHL

January 15, 2020

NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomas

January 14, 2020

Survival data reported from largest CAR T trial in B-cell lymphoma

December 20, 2019